You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Details for Patent: 9,669,021

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,669,021 protect, and when does it expire?

Patent 9,669,021 protects KYNMOBI and is included in one NDA.

This patent has forty-seven patent family members in nineteen countries.

Summary for Patent: 9,669,021

Title:	Sublingual apomorphine
Abstract:	Disclosed are methods of treating Parkinson's disease by (i) providing a pharmaceutical composition in unit dosage form that is a film having a first portion including apomorphine particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent, where the film contains the acid addition salt of apomorphine in an amount effective to treat Parkinson's disease, and (ii) administering the film by placing the film sublingually in the mouth of the subject and contacting sublingual mucosal tissue with the film.
Inventor(s):	Giovinazzo; Anthony John (Caledon, CA), Hedden; David Bruce (Ann Arbor, MI), De Somer; Marc L. (Winchester, MA), Bryson; Nathan John (Toronto, CA)
Assignee:	Sunovion Pharmaceuticals Inc. (Marlborough, MA)
Application Number:	14/971,532
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 9,669,021

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-001	May 21, 2020		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE	⤷ Try a Trial
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-002	May 21, 2020		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE	⤷ Try a Trial
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-003	May 21, 2020		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE	⤷ Try a Trial
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-004	May 21, 2020		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,669,021

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010259971	⤷ Try a Trial
Australia	2017200329	⤷ Try a Trial
Australia	2019200308	⤷ Try a Trial
Australia	2021201259	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.